Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company, Wednesday announced that it has appointed Matthew Greenhawt, as its Chief Medical Officer.
According to the company, Greenhawt is an internationally recognized expert in allergy and immunology with particular expertise in food allergy, anaphylaxis, patient-centered care, and health services and health policy research.
He takes over from Gary Slatko who was serving as the interim Chief Medical Officer.
Most recently, Greenhawt served as Chief Medical Officer of the Asthma and Allergy Foundation of America. Prior to this, he was the Professor of Pediatrics at Childrens Hospital Colorado and the University of Colorado School of Medicine.
In pre-market, AQST shares were trading at $3.90, up 0.52% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.